European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

Autor: Babjuk, M, Burger, M, Capoun, O, Cohen, D, Comperat, EM, Escrig, JLD, Gontero, P, Liedberg, F, Masson-Lecomte, A, Mostafid, AH, Palou, J, van Rhijn, BWG, Roupret, M, Shariat, SF, Seisen, T, Soukup, V, Sylvester, RJ

Publikováno v: EUROPEAN UROLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Context: The European Association of Urology (EAU) has released an updated version of the guidelines on non-muscle-invasive bladder cancer (NMIBC). Objective: To present the 2021 EAU guidelines on NMIBC. Evidence acquisition: A broad and comprehensiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9ba97cdf8dbcac4c39e38bea91f5ac2b
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6253

Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels.

Autor: Mertens LS; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: l.mertens@nki.nl., Bruins HM; Department of Urology, Zuyderland Medical Center, Sittard-Heerlen, The Netherlands., Contieri R; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Babjuk M; Department of Urology, Teaching Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Rai BP; Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Puig AC; Department of Urology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Escrig JLD; Department of Urology, Instituto Valenciano de Oncologia, Valencia, Spain., Gontero P; Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienca, Torina School of Medicine, Turin, Italy., van der Heijden AG; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Liedberg F; Department of Urology, Skane University Hospital, Malmö, Sweden; Institute of Translational Medicine, Lund University, Malmö, Sweden., Martini A; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA., Masson-Lecomte A; Department of Urology, Saint-Louis Hospital, AP-HP, Paris Cité University, Paris, France., Meijer RP; Department of Oncological Urology, University Medical Center Utrecht, Utrecht, The Netherlands., Mostafid H; Department of Urology, Royal Surrey Hospital, Guildford, UK., Neuzillet Y; Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France., Pradere B; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France., Redlef J; Patient Representative, European Association of Urology Guidelines Office, Arnhem, The Netherlands., van Rhijn BWG; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., Rouanne M; Department of Urology, Foch Hospital, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France., Rouprêt M; GRC 5, Predictive Onco-Urology, Sorbonne University, Department of Urology, Pitié-Salpetriere Hospital, Paris, France., Sæbjørnsen S; Patient Representative, European Association of Urology Guidelines Office, Arnhem, The Netherlands., Seisen T; GRC 5, Predictive Onco-Urology, Sorbonne University, Department of Urology, Pitié-Salpetriere Hospital, Paris, France., Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Soria F; Division of Urology, Department of Surgical Sciences, AOU Citta della Salute e della Scienca, Torina School of Medicine, Turin, Italy., Soukup V; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic., Thalmann G; Department of Urology, Inselspital, University Hospital Bern, Bern, Switzerland., Xylinas E; Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université Paris Cité, Paris, France., Mariappan P; Edinburgh Bladder Cancer Surgery, University of Edinburgh, Western General Hospital, Edinburgh, UK., Alfred Witjes J; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Jun 20. Date of Electronic Publication: 2024 Jun 20.

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Autor: Babjuk M; Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: Marek.Babjuk@fnmotol.cz., Burger M; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., Compérat EM; Department of Pathology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, UPMC Paris VI, Paris, France., Gontero P; Division of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy., Mostafid AH; Department of Urology, Royal Surrey County Hospital, Guildford, Surrey, UK., Palou J; Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain., van Rhijn BWG; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Rouprêt M; Urology Department, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France., Shariat SF; Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Sylvester R; European Association of Urology Guidelines Office, Brussels, Belgium., Zigeuner R; Department of Urology, Medical University of Graz, Graz, Austria., Capoun O; Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic., Cohen D; Department of Urology, Royal Free London NHS Foundation Trust, London, UK., Escrig JLD; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Hernández V; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Peyronnet B; Department of Urology, University of Rennes, Rennes, France., Seisen T; Urology Department, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France., Soukup V; Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Publikováno v: European urology [Eur Urol] 2019 Nov; Vol. 76 (5), pp. 639-657. Date of Electronic Publication: 2019 Aug 20.